drugset

drugset / Trial / NCT00875966

Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions

NCT00875966 ↗

Phase 1 Completed 42 enrolled Sandoz

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the bioequivalence of Azithromycin 200mg/5mL oral suspension.

Timeline

Start: 2004-08
Primary completion: 2004-10
Completion: 2004-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azithromycin	Small molecule	600 mg	Oral

Indications